Statins reduce cardiovascular morbidity and mortality in appropriately selected patients. However, statin-associated myopathy is a significant risk associated with these agents. Recently, variation in the SLCO1B1 gene was reported to predict simvastatin-associated myopathy. The aim of this study was to replicate association of the rs4149056 variant in SLCO1B1 with severe statin-associated myopathy in a cohort of patients using a variety of statin medications and to investigate the association with specific statin types. We identified 25 cases of severe statin-associated myopathy and 84 controls matched for age, gender, statin type and dose. The rs4149056 variant in SLCO1B1 was not significantly associated with myopathy in this group as a whole. However, when subjects were stratified by statin type, the SLCO1B1 rs4149056 genotype was significantly associated with myopathy in patients who received simvastatin, but not in patients who received atorvastatin. Our findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/tpj.2010.92 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid Detection of Polymorphisms Using Duplex Fluorescence Melting Curve Analysis: Implications for Personalized Drug Dosing in Clinical Settings.
Drug Des Devel Ther
November 2024
Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, 518038, People's Republic of China.
Article Synopsis
- The study aims to develop a quick and accurate method for detecting genetic variants related to drug transport, which is crucial for personalized medicine, using Duplex Fluorescence Melting Curve Analysis (DFMCA).
- Researchers collected blood samples from 54 individuals, extracted DNA, and performed PCR to analyze two common genetic polymorphisms, confirming the method's effectiveness with melting curve analysis.
- The DFMCA method proved to be efficient, accurately identifying genotypes within 2 hours and showing reliability in detecting allele frequencies consistent with prior studies among Han Chinese individuals.
Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study.
Atherosclerosis
January 2025
Laboratoire de Biométrie et Biologie Evolutive UMR CNRS 5558, Université Lyon 1, Université de Lyon, Villeurbanne, France; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.
Background And Aims: Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend dose adjustment for statin treatment according to known SLCO1B1 genotype to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias.
View Article and Find Full Text PDFA Rapid and Scalable Multiplex PCR-Based Next-Generation Amplicon Sequencing Method for Familial Hypercholesterolemia Genetic Screening.
J Appl Lab Med
November 2024
CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
Article Synopsis
- Familial hypercholesterolemia (FH) is a genetic condition that causes high LDL cholesterol levels and is often not diagnosed; genetic tests can identify variants in key genes in about 80% of patients.
- A new sequencing method was developed using multiplex primers to analyze the LDLR, APOB, and PCSK9 genes, as well as specific variants related to statin effects, aiming to make the process faster, cheaper, and scalable.
- The method showed high accuracy with no variant dropouts, successfully detected known pathogenic variants, and suggested that some patients might need lower doses of statins; the entire testing process can now be done in about 3 hours for under $50.
Allelic frequencies of polymorphism c.521T>C (rs4149056) favor preemptive genotyping in Armenia.
Drug Metab Pers Ther
September 2024
Department of Medical Genetics, Yerevan State Medical University, Yerevan, Armenia.
Objectives: Statins represent an important pharmacological factor for the prevention of cardiovascular diseases but may also cause severe cases of myotoxicity. Numerous studies have described the association of the gene variant c.521C with statin-induced myopathy across different populations.
View Article and Find Full Text PDFLarge-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population.
Hum Genomics
March 2024
Clinical Genomics, Centre for Genomic Medicine, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.
Background: SLCO1B1 plays an important role in mediating hepatic clearance of many different drugs including statins, angiotensin-converting enzyme inhibitors, chemotherapeutic agents and antibiotics. Several variants in SLCO1B1 have been shown to have a clinically significant impact, in relation to efficacy of these medications. This study provides a comprehensive overview of SLCO1B1 variation in Saudi individuals, one of the largest Arab populations in the Middle East.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!